Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications

JCO Precis Oncol. 2024 Jun:8:e2400204. doi: 10.1200/PO.24.00204.

Carlos Torrado¹, Ruth Plummer², Timothy A Yap^{1

3

4}

¹ Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.
² Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kigdom.
³ Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁴ Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract

Biomarker-based patient selection and rational combinations show promise in expanding the use of PARP inhibitors.